Kushida CA - Search Results

1

Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study.

Bogan RK, Bornemann MA, Kushida CA, Trân PV, Barrett RW; XP060 Study Group. Bogan RK, et al. Among authors: kushida ca. Mayo Clin Proc. 2010 Jun;85(6):512-21. doi: 10.4065/mcp.2009.0700. Mayo Clin Proc. 2010. PMID: 20511481 Free PMC article. Clinical Trial.

2

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome.

Allen R, Becker PM, Bogan R, Schmidt M, Kushida CA, Fry JM, Poceta JS, Winslow D. Allen R, et al. Among authors: kushida ca. Sleep. 2004 Aug 1;27(5):907-14. doi: 10.1093/sleep/27.5.907. Sleep. 2004. PMID: 15453549 Clinical Trial.

3

A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.

Kushida CA, Walters AS, Becker P, Thein SG, Perkins AT, Roth T, Canafax D, Barrett RW; XP021 Study Group. Kushida CA, et al. Sleep. 2009 Feb;32(2):159-68. doi: 10.1093/sleep/32.2.159. Sleep. 2009. PMID: 19238802 Free PMC article. Clinical Trial.

4

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial.

Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP045 Study Group. Walters AS, et al. Among authors: kushida ca. Clin Neuropharmacol. 2009 Nov-Dec;32(6):311-20. doi: 10.1097/WNF.0b013e3181b3ab16. Clin Neuropharmacol. 2009. PMID: 19667976 Clinical Trial.

5

Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.

Kushida CA, Shapiro CM, Roth T, Thorpy MJ, Corser BC, Ajayi AO, Rosenberg R, Roy A, Seiden D, Dubow J, Dauvilliers Y. Kushida CA, et al. Sleep. 2022 Jun 13;45(6):zsab200. doi: 10.1093/sleep/zsab200. Sleep. 2022. PMID: 34358324 Free PMC article. Clinical Trial.

6

Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.

Roth T, Dauvilliers Y, Thorpy MJ, Kushida C, Corser BC, Bogan R, Rosenberg R, Dubow J, Seiden D. Roth T, et al. CNS Drugs. 2022 Apr;36(4):377-387. doi: 10.1007/s40263-022-00904-6. Epub 2022 Apr 5. CNS Drugs. 2022. PMID: 35380374 Free PMC article. Clinical Trial.

7

Proteomic insights into the pathophysiology of periodic limb movements and restless legs syndrome.

Cederberg KLJ, Peris Sempere V, Lin L, Zhang J, Leary EB, Moore H, Morse AM, Blackman A, Schweitzer PK, Kotagal S, Bogan R, Kushida CA; STAGES cohort investigator group; Mignot E. Cederberg KLJ, et al. Among authors: kushida ca. Sleep Health. 2024 Feb;10(1S):S161-S169. doi: 10.1016/j.sleh.2023.06.008. Epub 2023 Aug 9. Sleep Health. 2024. PMID: 37563071

8

Restless legs syndrome symptoms in primary care: a prevalence study.

Nichols DA, Allen RP, Grauke JH, Brown JB, Rice ML, Hyde PR, Dement WC, Kushida CA. Nichols DA, et al. Among authors: kushida ca. Arch Intern Med. 2003 Oct 27;163(19):2323-9. doi: 10.1001/archinte.163.19.2323. Arch Intern Med. 2003. PMID: 14581252

9

Factor analysis of the International Restless Legs Syndrome Study Group's scale for restless legs severity.

Allen RP, Kushida CA, Atkinson MJ; RLS QoL Consortium. Allen RP, et al. Among authors: kushida ca. Sleep Med. 2003 Mar;4(2):133-5. doi: 10.1016/s1389-9457(02)00193-4. Sleep Med. 2003. PMID: 14592343

10

Ropinirole in the treatment of restless legs syndrome.

Kakar RS, Kushida CA. Kakar RS, et al. Among authors: kushida ca. Expert Rev Neurother. 2005 Jan;5(1):35-42. doi: 10.1586/14737175.5.1.35. Expert Rev Neurother. 2005. PMID: 15853472 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page